12:00 AM
Feb 18, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Jakavi ruxolitinib regulatory update

The U.K.'s NICE issued draft guidance recommending against the use of Jakavi ruxolitinib from Novartis to treat disease-related splenomegaly or symptoms in adults with chronic idiopathic myelofibrosis, post-polycythemia vera or essential thrombocythemia myelofibrosis - its approved indications. The committee said the drug was effective in reducing spleen size and in treating symptoms, including itch and fatigue, and that it was "plausible" that Jakavi offers a survival benefit. NICE also said that Jakavi is "innovative" and that it would...

Read the full 368 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >